I-131 Use In Nuclear Medicine: Mechanisms, Safety, And Protocols
The following learning assessment is for the maiCE article I-131 Use in Nuclear Medicine: Mechanisms, Safety, and Protocols.
First, open the CE article by clicking here.
Then, complete the assessment by entering your name and email and selecting "Start" below.
This CE activity is worth 1.0 Category A CE credit (RCEEM AHRA), accepted by the ARRT and the NMTCB.
A score of 75% or greater must be scored to obtain credit.
Your Certificate of CE Completion will be emailed to the address you use to register this test.
Your name will appear on your Certificate of CE Completion as you enter it below. Please include the full name you would Read morelike on your certificate as well as any credentials.
This CE activity is distributed compliments of maiServices to our valued customers and partners. If you are not already part of our social network, completing this CE activity will subscribe you to our industry and blog updates, as well as qualify you for more complimentary CE credits from maiServices.
For more updates, news and connections, find maiServices on Facebook, Twitter, Google+, LinkedIn and the maiBlog.
For questions related to this CE exam, please contact Jennifer Gutiérrez at [email protected]/* */
- 1.
The clinical properties of I-131 are due to what?
- A.
Half-life of the isotope
- B.
Size of the isotope
- C.
Gamma-radiation emitted by the isotope
- D.
Beta-particles emitted by the isotope
- E.
Method of delivery of the isotope
Correct Answer
D. Beta-particles emitted by the isotopeExplanation
The clinical properties of I-131 are due to the beta-particles emitted by the isotope. Beta-particles are high-energy particles that can penetrate tissues and cause damage to cancer cells. They are used in radiation therapy to target and destroy cancer cells. I-131 is commonly used in the treatment of thyroid cancer because it specifically targets the thyroid gland and delivers a high dose of radiation to the cancer cells while minimizing damage to surrounding healthy tissues.Rate this question:
-
- 2.
The half-life of I-131 is approximately
- A.
8 seconds
- B.
8 minutes
- C.
8 days
- D.
8 months
- E.
8 years
Correct Answer
C. 8 daysExplanation
The half-life of I-131 is approximately 8 days. This means that it takes 8 days for half of the initial amount of I-131 to decay into other elements. After another 8 days, half of the remaining I-131 will decay, and so on. The half-life is a measure of the stability of a radioactive substance, and in the case of I-131, it has a relatively short half-life compared to other radioactive isotopes.Rate this question:
-
- 3.
What type of radiation does I-131 emitt?
- A.
Alpha
- B.
Beta
- C.
Gamma
- D.
A & b
- E.
B & c
Correct Answer
E. B & cExplanation
I-131 emits both beta and gamma radiation. Alpha radiation is not emitted by I-131.Rate this question:
-
- 4.
I-131 is taken up by thyroid tissue in the body because iodine is a constituent of thyroid ___________ .
- A.
Tissue
- B.
Secretion
- C.
Hormone
- D.
Enzyme
Correct Answer
C. HormoneExplanation
I-131 is taken up by thyroid tissue in the body because iodine is a constituent of thyroid hormone. The thyroid gland produces hormones called thyroxine (T4) and triiodothyronine (T3), which are essential for regulating the body's metabolism. These hormones contain iodine atoms, and the thyroid gland actively takes up iodine from the bloodstream to produce and release these hormones. Therefore, when I-131, a radioactive form of iodine, is introduced into the body, it is readily absorbed by the thyroid tissue due to its affinity for iodine and its involvement in thyroid hormone production.Rate this question:
-
- 5.
Approximately what amount of I-131 in the bloodstream is deposited in thyroid tissue?
- A.
10%
- B.
20%
- C.
30%
- D.
40%
- E.
50%
Correct Answer
C. 30%Explanation
Approximately 30% of I-131 in the bloodstream is deposited in thyroid tissue. This suggests that a significant portion of the I-131 is absorbed by the thyroid gland, indicating its affinity for this specific tissue.Rate this question:
-
- 6.
When did I-131 begin its use in treatment of thyroid cancer?
- A.
1930s
- B.
1940s
- C.
1950s
- D.
1960s
- E.
1970s
Correct Answer
B. 1940sExplanation
In the 1940s, I-131 began its use in the treatment of thyroid cancer.Rate this question:
-
- 7.
In addition to thyroid cancer, what is another indication for the use of I-131 therapy?
- A.
Thyroiditis
- B.
Hyperthyroidism
- C.
Hypothyroidism
- D.
A & b
- E.
B & c
Correct Answer
B. HyperthyroidismExplanation
I-131 therapy is commonly used to treat hyperthyroidism, a condition where the thyroid gland produces an excessive amount of thyroid hormone. This therapy involves administering a radioactive form of iodine (I-131) which selectively destroys the overactive thyroid cells, helping to normalize hormone production. It is an effective treatment option for hyperthyroidism, along with other treatments such as medications or surgery.Rate this question:
-
- 8.
Precautions to protect not only patients, but also the general public that come in contact with them, are taken because:
- A.
I-131 radiation is detectable outside of the patient body as well as excreted through their body fluid
- B.
Diseases that I-131 treat are communicable
- C.
I-131 treatment can cause susceptibility to communicable disease
- D.
All of the above
Correct Answer
A. I-131 radiation is detectable outside of the patient body as well as excreted through their body fluidExplanation
Precautions are taken to protect not only patients but also the general public because I-131 radiation is detectable outside of the patient's body and can be excreted through their body fluids. This means that individuals who come in contact with the patient may be exposed to the radiation. Therefore, it is necessary to take precautions to prevent any potential harm to others. The other options mentioned, such as diseases that I-131 treats being communicable and I-131 treatment causing susceptibility to communicable diseases, are not relevant to the given explanation.Rate this question:
-
- 9.
In what form is I-131 delivered for treatment?
- A.
Injectable fluid
- B.
Pill
- C.
Transdermal patch
- D.
Radioactive seeds
- E.
A & b
Correct Answer
B. PillExplanation
I-131 is delivered for treatment in the form of a pill.Rate this question:
-
- 10.
Which of the following are possible short-term risks of I-131 treatment?
- A.
Swelling of salivary glands
- B.
Nausea
- C.
Stomach irritation
- D.
Tenderness in the neck area
- E.
All of the above
Correct Answer
E. All of the aboveExplanation
The correct answer is "all of the above." I-131 treatment is a radioactive iodine therapy used to treat thyroid conditions. Short-term risks of this treatment include swelling of salivary glands, nausea, stomach irritation, and tenderness in the neck area. These side effects are common and expected after I-131 treatment.Rate this question:
-
- 11.
What agencies are responsible for regulating the clinical and environmental exposure to I-131?
- A.
NRC
- B.
EPA
- C.
FDA
- D.
WHO
- E.
All of the above
Correct Answer
E. All of the aboveExplanation
All of the above agencies are responsible for regulating the clinical and environmental exposure to I-131. The NRC (Nuclear Regulatory Commission) regulates the use of I-131 in medical settings, ensuring that proper procedures are followed to minimize exposure. The EPA (Environmental Protection Agency) regulates environmental exposure to I-131, setting limits and guidelines to protect public health. The FDA (Food and Drug Administration) regulates the use of I-131 in food and drugs, ensuring safety and proper labeling. The WHO (World Health Organization) also provides guidelines and recommendations for the safe use and handling of I-131.Rate this question:
-
- 12.
Progressive imaging scans of I-131 treatment of thyroid cancer should show __________ in thyroid appearance/uptake.
- A.
Decrease
- B.
Increase
- C.
No change
Correct Answer
A. DecreaseExplanation
Progressive imaging scans of I-131 treatment of thyroid cancer should show a decrease in thyroid appearance/uptake. This is because I-131 is a radioactive iodine that is used to destroy thyroid cells. As the treatment progresses, the radioactive iodine targets and kills the cancerous thyroid cells, leading to a decrease in their appearance and uptake on the imaging scans. Therefore, a decrease in thyroid appearance/uptake is expected and indicates a positive response to the treatment.Rate this question:
-
- 13.
Thyroid cancer is most often found in ________ persons.
- A.
Older
- B.
Younger
- C.
Obese
- D.
A & b
- E.
B & c
Correct Answer
B. YoungerExplanation
Thyroid cancer is most often found in younger persons. This is because the incidence of thyroid cancer tends to peak in individuals between the ages of 20 and 55. It is relatively rare in children and older adults. While obesity has been associated with an increased risk of certain types of cancer, including thyroid cancer, it is not the most common demographic characteristic associated with thyroid cancer. Therefore, the correct answer is younger.Rate this question:
-
- 14.
What disease is I-131 Tostitumomab indicated to treat?
- A.
Hodgkin's lymphoma
- B.
Non-Hodgkin's lymphoma
- C.
Grave's disease
- D.
Multi-nodular goiter
- E.
Hyperthyroidism
Correct Answer
B. Non-Hodgkin's lymphomaExplanation
I-131 Tositumomab is indicated to treat non-Hodgkin's lymphoma.Rate this question:
-
- 15.
How many days does the NRC recommend a restriction in exposure to others for a patient who has undergone I-131 therapy with a dose of 70mCi?
- A.
1 day
- B.
2 days
- C.
3 days
- D.
5 days
- E.
No restriction
Correct Answer
B. 2 daysExplanation
The NRC recommends a restriction of 2 days in exposure to others for a patient who has undergone I-131 therapy with a dose of 70mCi. This is because I-131 is a radioactive isotope that emits radiation, and the restriction is necessary to minimize the risk of radiation exposure to others.Rate this question:
-
- 16.
A 2011 study specifically concerning 10 CFR 35.75 and I-131 patients sought to:
- A.
Clarify the NRC's position on release of I-131 therapy patients
- B.
Decrease the occurrence of thyroid cancer
- C.
Identify the frequency of I-131 treatment
- D.
Clarify the NRC's position on dosage of I-131 therapy patients
Correct Answer
A. Clarify the NRC's position on release of I-131 therapy patientsExplanation
The correct answer is to clarify the NRC's position on release of I-131 therapy patients. This means that the study aimed to provide clear guidelines or instructions from the NRC (Nuclear Regulatory Commission) regarding the release of patients who have undergone I-131 therapy. The study likely sought to address any ambiguity or confusion in the existing regulations and provide specific guidance on when and under what conditions these patients can be released.Rate this question:
-
- 17.
Pertaining to details surrounding release of patients after I-131 treatment, licensees must consider the ______________ .
- A.
Extent of the patient's disease
- B.
Destination of the patient after release
- C.
Number of therapy sessions the patient has undergone
- D.
All of the above
- E.
None of the above
Correct Answer
B. Destination of the patient after releaseExplanation
Licensees must consider the destination of the patient after release when determining the details surrounding the release of patients after I-131 treatment. This is important because the patient's destination will determine the necessary precautions and instructions for travel, as well as any potential risks or restrictions that may apply in the specific location.Rate this question:
-
- 18.
The NRC regulations regarding I-131 treatment are heavily reliant on the ___________ and their _________ .
- A.
Patient; judgement
- B.
Licensee; judgement
- C.
Licensee; experience
- D.
Patient; disease
- E.
Patient; family
Correct Answer
B. Licensee; judgementExplanation
The NRC regulations regarding I-131 treatment are heavily reliant on the licensee's judgement. This means that the person or organization responsible for administering the treatment must use their professional expertise and decision-making skills to ensure the safety and effectiveness of the treatment. The regulations trust the licensee to make informed decisions based on their knowledge and experience in order to protect the patient and comply with the guidelines.Rate this question:
-
- 19.
Why is I-131 therapy used in post-operative treatment of thyriod cancer?
- A.
To strengthen the thyroid tissue
- B.
To ablate residual malignant cells
- C.
For palliative treatment
- D.
To treat metastasis
Correct Answer
B. To ablate residual malignant cellsExplanation
I-131 therapy is used in post-operative treatment of thyroid cancer to ablate residual malignant cells. This therapy involves the administration of radioactive iodine, which is taken up by any remaining cancer cells in the body. The high-energy radiation emitted by the iodine destroys these cancer cells, reducing the risk of recurrence or spread of the disease. This treatment is effective in targeting and eliminating any remaining cancer cells that may not have been completely removed during surgery.Rate this question:
-
- 20.
Which of the following statements about the mechanism of action for Technetium-99m (Tc-99m) in nuclear medicine imaging is true?
- A.
Tc-99m primarily emits alpha particles, which are crucial for imaging purposes.
- B.
Tc-99m is used because it has a long half-life, allowing for extended imaging procedures.
- C.
Tc-99m emits gamma rays, which are detected by gamma cameras to create diagnostic images.
- D.
Tc-99m directly interacts with DNA to produce high-resolution images of cellular structures.
Correct Answer
C. Tc-99m emits gamma rays, which are detected by gamma cameras to create diagnostic images.Explanation
Technetium-99m (Tc-99m) is widely used in nuclear medicine because it emits gamma rays, which can be detected by gamma cameras to create detailed images of the body's internal structures. Its short half-life of approximately 6 hours makes it ideal for diagnostic imaging without exposing the patient to prolonged radiation. The other options are incorrect: Tc-99m does not emit alpha particles, has a relatively short half-life (not long), and does not interact directly with DNA for imaging.Rate this question:
-
Quiz Review Timeline +
Our quizzes are rigorously reviewed, monitored and continuously updated by our expert board to maintain accuracy, relevance, and timeliness.
-
Current Version
-
Aug 25, 2024Quiz Edited by
ProProfs Editorial Team -
Dec 06, 2011Quiz Created by
Maiservices
Back to top